Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CAMP vs NVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NVS Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–1 Matrix Metrics)

NVS Overall Winner 6-Pillar Tally: CAMP 1 – 4 NVS (1 Tie) Matrix Metrics: CAMP 1 – 8 NVS

As of Nov 17, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CAMP carries a Unified Composite Score of 41.9/100 (SELL) at $3.95 (N/M Forward P/E, -991.8% operating margin), whereas NVS carries 41.9/100 (SELL) at $159.20 (16.1x Forward P/E, 34.0% operating margin).

  • Growth vs. Quality Trade-Off: NVS earns the overall head-to-head edge with a stronger Unified Composite Score (41.9/100 SELL vs. CAMP 41.9/100 SELL) and 0.31β · 26% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although NVS compares more favorably head-to-head, both CAMP (41.9/100 SELL) and NVS (41.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAMP vs NVS
CAMP NASDAQ
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$3.95
+2.33% 1D
Market Cap $238.5M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol 1.34β · 94% Vol
Unified Composite Score
41.9 / 100 SELL
Tech 30.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 53.3 · SMA20: $3.82 · SMA50: $3.84
NVS NYSE Head-to-Head Winner
Novartis AG
Pharmaceutical Preparations
$159.20
-0.62% 1D
Market Cap $303.1B
TTM Revenue $40.5B
Forward P/E 16.1x
Beta / 30D Vol 0.31β · 26% Vol
Unified Composite Score
41.9 / 100 SELL
Tech 32.0 Fund 38.0 Flow 50.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.0% over 20 days), RSI 57
RSI-14: 56.9 · SMA20: $159.42 · SMA50: $149.58

6-Pillar Scorecard Institutional Category Breakdown (CAMP 1 – 4 NVS)

Columns: Metric · CAMP · NVS
1. Valuation Multiples NVS
Forward P/E N/M 16.1x
Trailing P/E N/M 30.6x
PEG Ratio N/M 3.82x
EV / Revenue 26.6x 7.5x
2. Growth & Scale CAMP
Revenue Growth (YoY) +138.9% +4.7%
Earnings Growth (YoY) +0.0% -68.8%
TTM Revenue (USD) $5.3M $40.5B
Market Cap $238.5M $303.1B
3. Profitability & Quality NVS
Gross Margin N/A 75.2%
Operating Margin -991.8% 34.0%
Net Profit Margin 0.0% 17.5%
Return on Equity (ROE) -146.1% 24.3%
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) -$26M $17.0B EBITDA
Cash Flow Margin N/A 42.0% EBITDA Mgn
Net Cash / Leverage $97M Net Cash $19.71 Book/Sh · 24.3% ROE
Dividend Yield None (0.00%) 2.95%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 16.9% (6th %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat NVS
OpEx & R&D Intensity N/A 41.2% of Rev ($16.7B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAMP (1) vs NVS (8)
Institutional Metric CAMP NVS Criterion Row Edge
Market Capitalization
Scale
$238.5M $303.1B Larger Scale NVS
Trailing P/E Ratio
Valuation
N/M 30.6x Lower Multiple NVS
Forward P/E Ratio
Valuation
N/M 16.1x Lower Multiple NVS
Revenue Growth (YoY)
Growth
+138.9% +4.7% Higher Growth CAMP
Operating Margin (TTM)
Profitability
-991.8% 34.0% Higher Margin NVS
Net Profit Margin
Profitability
0.0% 17.5% Higher Margin NVS
Return on Equity (ROE)
Capital Efficiency
-146.1% 24.3% Higher ROE NVS
52-Week Range Position
Momentum
22% ($3–$8) 76% ($123–$170) Stronger Trend NVS
Beta / 30D Volatility
Risk Regime
1.34β · 94% Vol 0.31β · 26% Vol Lower Realized Risk NVS
Unified Institutional Score
Composite Signal
41.9 / 100 (SELL) 41.9 / 100 (SELL) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$5.3M $40.5B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 75.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 26.6x EV/Rev 3.82x PEG · 7.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$26M ($97M Net Cash) $17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAMP +19.81 pp
CAMP: +25.8% · NVS: +5.99%
3M Horizon NVS +14.36 pp
CAMP: -15.05% · NVS: -0.69%
6M Horizon NVS +10.64 pp
CAMP: -4.82% · NVS: +5.82%
1Y Horizon NVS +24.95 pp
CAMP: -3.66% · NVS: +21.29%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CAMP vs NVS. Trailing 12-month operating profitability (CAMP -991.8% vs NVS 34.0%) and valuation multiples (CAMP N/M vs NVS 16.1x Forward P/E) are benchmarked directly in Pillar 4 below.

CAMP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.3M
Gross MarginN/A
Op. Margin-991.8%
ROE / Fwd P/E-146.1% · N/M
NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 16.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $303.1B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published

Investor FAQ CAMP vs NVS Key Questions & Quantitative Answers

As of Nov 17, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CAMP carries a Unified Composite Score of 41.9/100 (SELL) at $3.95 (N/M Forward P/E, -991.8% operating margin), whereas NVS carries 41.9/100 (SELL) at $159.20 (16.1x Forward P/E, 34.0% operating margin). Growth vs. Quality Trade-Off: NVS earns the overall head-to-head edge with a stronger Unified Composite Score (41.9/100 SELL vs. CAMP 41.9/100 SELL) and 0.31β · 26% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although NVS compares more favorably head-to-head, both CAMP (41.9/100 SELL) and NVS (41.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

CAMP leads the Growth & Scale pillar: CAMP posts +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin), compared with NVS at +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin). On trailing 12-month operating scale, CAMP generates $5.3M in USD-normalized revenue versus $40.5B for NVS. In operating R&D and SG&A reinvestment, CAMP deploys N/A (0 90-day corporate R&D disclosures) versus 41.2% of Rev ($16.7B) (0 disclosures) for NVS.

NVS screens cheaper on headline valuation multiples. CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin), whereas NVS trades at 16.1x Forward P/E, 30.6x Trailing P/E, 3.82x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAMP (-146.1% ROE) versus NVS (24.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk). By comparison, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 26% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.